drugset / Trial / NCT00824447

Long-term Efficacy and Safety Study With Oralgen Grass Pollen

NCT00824447 ↗

Phase 2/3 Completed 356 enrolled Artu Biologicals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to give additional information on the efficacy, safety and local effects (tolerability) of a dose of sublingual immunotherapy administered once a day, during a second grass pollen season.

Timeline

Start
2007-08
Primary completion
2008-08
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oralgen Vaccine 9500 unknown Other
Comparator Oralgen Vaccine 19000 unknown Other

Indications